YOLFTbeta
NextCure  Inc

NextCure  Inc

NXTC · NASDAQ · Healthcare / Biotechnology

6.40USD+0.17 (+2.73%)

Price History

Full chart

Market Stats

Previous Close6.23
Open6.00
Day Range5.96 – 6.57
52-Week Range1.55 – 15.74
Volume37.72K
Market Cap23.25M
P/E (TTM)0.00
Forward P/E0.00
EPS-8.28
Dividend Yield0.00%
Beta1.34
50-Day Avg6.11
200-Day Avg8.65

About

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Michael S. Richman MSBA
  • Employees40
  • Headquarters2850 Quarry Lake Drive, Baltimore, MD, United States, 21209, USA
  • Websitehttps://www.nextcure.com

Leadership

  • Mr. Michael S. Richman MSBACo-Founder, CEO, President & Director · b. 1961
  • Dr. Timothy Mayer Ph.D.Chief Operating Officer · b. 1965
  • Dr. Udayan Guha M.D., Ph.D.Chief Medical Officer · b. 1972
  • Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · b. 1957
  • Mr. Steven P. Cobourn CPAChief Financial Officer · b. 1963
  • Mr. Kevin G. ShawSenior VP & General Counsel · b. 1974
  • Mr. Sourav Kundu Ph.D.Senior Vice President of Development & Manufacturing · b. 1960
  • Dr. Sebastien Maloveste Ph.D.Senior Vice President of Business Development

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue006.35M22.38M00000
Growth (%)---+252.58%-100.00%----
Cost of Revenue582.00K1.68M34.22M46.55K4.30M4.48M3.68M2.87M2.19M
Gross Profit-582.00K-1.68M-27.87M22.38M-4.30M-4.48M-3.68M-2.87M-2.19M
Gross Margin---439.09%100.00%-----
Operating Expense14.97M21.52M9.61M63.60M66.47M71.43M63.95M56.88M55.43M
Operating Income-15.55M-23.20M-37.48M-41.23M-70.77M-75.91M-67.64M-59.75M-57.62M
Operating Margin---590.55%-184.22%-----
EBITDA-14.97M-21.10M-34.79M-37.81M-65.14M-71.78M-59.04M-54.34M-53.66M
EBITDA Margin---548.20%-168.97%-----
Net Income-15.47M-22.80M-33.74M-33.19M-69.39M-69.43M-62.72M-55.65M-55.84M
Net Income Margin---531.54%-148.32%-----
R&D12.95M19.79M34.22M46.55M50.19M54.20M47.93M41.49M44.92M
R&D as % of Total Revenue--539.09%208.03%-----
Interest Expense00209.00K183.00K77.00K5.30M---
Interest Expense % of Total Revenue--3.29%0.82%-----

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.47M147.63M356.17M306.64M242.39M184.16M128.04M80.86M50.18M
Total Liabilities43.88M194.57M34.68M12.92M9.00M16.63M13.62M15.39M15.24M
Total Equity-24.41M-46.94M321.48M293.72M233.39M167.53M114.42M65.47M34.94M
Cash8.43M135.17M34.09M32.77M12.34M26.63M13.08M27.73M25.98M
Total Debt964.00K587.00K5.13M3.47M-7.12M6.61M5.95M5.15M
Net Debt-7.46M-134.59M-28.96M-29.30M-12.34M-19.51M-6.48M-21.78M-20.83M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.51M7.99M-35.62M-44.95M-57.24M-53.89M-52.97M-40.80M-49.61M
Investing Cash Flow-8.65M-3.06M-303.92M43.52M36.60M67.98M39.27M55.31M25.56M
Financing Cash Flow24.86M121.42M243.04M-1.42M-3.27M200.00K154.00K144.00K22.31M
Capital Expenditure8.65M3.06M3.37M7.13M2.36M2.12M820.00K474.00K0
Free Cash Flow-21.17M4.93M-38.99M-52.09M-59.60M-56.00M-53.79M-41.28M-49.61M
Dividends Paid00-------
FCF to OCF169.14%61.67%109.46%115.87%104.12%103.93%101.55%101.16%100.00%
Dividend Paid to FCF0.00%0.00%-------

Earnings

Report DateJun 10, 2019Aug 12, 2019Nov 12, 2019Mar 12, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Mar 21, 2024May 2, 2024Aug 1, 2024Nov 7, 2024Mar 19, 2025May 1, 2025Aug 7, 2025Nov 5, 2025Mar 6, 2026May 7, 2026Aug 6, 2026Nov 4, 2026
EPS Estimate-0.53-7.56-4.08-8.46-0.44-5.82-6.52-0.60-7.15-7.44-7.97-0.67-8.02-9.02-7.80-0.66-7.44-7.20-7.84-0.54-5.52-4.95-3.84-0.36-4.80-4.62-4.06-2.29-2.03-1.98-0.90
EPS Actual-4.46-7.32-4.44-4.080.33-6.36-7.08-0.54-7.20-7.80-7.80-0.61-8.88-7.80-8.16-0.62-6.96-7.68-6.12-0.52-6.26-6.60-4.92-0.41-4.68-11.29-3.22-0.81-1.87-1.84-
Surprise-741.51%3.17%-8.82%51.77%175.00%-9.28%-8.59%10.00%-0.70%-4.84%2.13%8.96%-10.72%13.53%-4.62%6.06%6.45%-6.67%21.94%3.70%-13.41%-33.33%-28.13%-13.89%2.50%-144.37%20.69%64.63%7.88%7.07%-
TimingAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap23.25M
Enterprise Value5.58M
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.52
Price / Book1.82
EPS-8.28
Book Value2.99
Revenue (TTM)0
Gross Profit (TTM)-54.20M
EBITDA-37.37M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-204.56%
Return on Assets-69.02%
Shares Outstanding4.58M
Shares Float2.93M
Beta1.34
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 2 analystsTarget 20.00
  • Buy
    2

Ownership Breakdown

Institutions
52.75%
Insiders
8.64%
Retail / Other
38.61%

Top Institutional Holders

  • Adage Capital Partners Gp LLC
    277.20K6.06%
  • Ikarian Capital, LLC
    238.30K5.21%
  • Sofinnova Ventures
    222.65K4.86%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    176.06K3.85%
  • Vanguard Capital Management, LLC
    160.47K3.51%
  • Pfizer Inc
    153.35K3.35%
  • Awm Investment Company Inc
    117.37K2.56%
  • Millennium Management LLC
    88.11K1.93%
  • BOOTHBAY FUND MANAGEMENT, LLC
    69.62K1.52%
  • Squadron Capital Management LLC
    64.46K1.41%
  • Renaissance Technologies Corp
    60.53K1.32%
  • Verdad Advisers, LP
    60.45K1.32%
  • Affinity Asset Advisors, LLC
    41.96K0.92%
  • Geode Capital Management, LLC
    31.09K0.68%
  • BlackRock Inc
    27.79K0.61%
  • Woodline Partners LP
    27.50K0.60%
  • CARDIFF PARK ADVISORS, LLC
    21.83K0.48%
  • Acadian Asset Management LLC
    18.98K0.41%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    123.28K2.69%
  • Fidelity Extended Market Index
    16.25K0.35%

Stock Splits

  • Jul 14, 20251:12